Ajanta Pharma Ltd (AJANTPHARM) is currently trading at 3,523.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ajanta Pharma is a specialty pharmaceutical formulation company focused on Branded Generics across India, Asia and Africa, complemented by a selective US generics business and institutional antimalarial supplies; it develops, manufactures and markets finished dosage formulations from seven manufacturing facilities with an advanced R&D centre and a large front-end salesforce in emerging markets. The business mix is heavily skewed to Branded Generics (71% of 9M FY2026 sales of Rs. 3,995 crore), with India (31%), Asia (23%) and Africa (17%) the primary markets; Ajanta emphasizes chronic therapies, claims ~50% of products are first-to-market, manages 500+ brands and deploys nearly 6,000 medical representatives globally. Financially Ajanta delivered resilient growth with 9M FY2026 consolidated revenue of Rs. 4,031 crore (16% year-on-year), adjusted EBITDA margin around 28% and net profit margin near 20%; US generics accelerated strongly with a 46% year-on-year rise in 9M revenues, driving much of the recent uplift in consolidated performance. The company’s R&D and manufacturing capabilities are key advantages: over 850 scientists, sustained R&D spend of about 5% of revenue, 50 active ANDAs with 19 pending approvals, and seven plants including two USFDA-approved facilities; strategic priorities emphasise new product launches, market share gains, country expansion, expense optimisation and digitalisation. Near-term headwinds include lower institutional antimalarial procurement in Africa and elevated receivable days (114 days in 9M FY2026) which reduced cash conversion to 36% for the period; management continues high cash payout history while balancing investment in launches and selective US filings to sustain growth.

Over the past 52 weeks, Ajanta Pharma Ltd has traded between a low of ₹2,335.00 and a high of ₹3,796.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ajanta Pharma Ltd has a market capitalization of approximately 44,234.87. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ajanta Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 38.98 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 44,234.87 Cr, Ajanta Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ajanta Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ajanta Pharma Ltd is 38.98. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Consolidated revenue from operations was about ₹1,625.96 crore (around ₹1,626 crore) and consolidated PAT rose to about ₹334 crore (₹334.22 crore).

Ravi Agrawal Trust, a promoter-group entity linked to Ajanta Pharma’s promoters, sold the shares.

Ajanta Pharma saw a promoter entity sell 34.5 lakh shares (2.8%) via a ₹1,024 crore block deal, and it also announced a semaglutide marketing agreement with Biocon.

Q2 FY26 revenue from operations was ₹1,354 crore, and consolidated net profit was ₹260 crore, compared with ₹1,187 crore revenue and ₹216 crore profit a year earlier.